OpGen (OPGN) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of OpGen (NASDAQ:OPGN) from a buy rating to a hold rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Separately, Alliance Global Partners assumed coverage on OpGen in a research report on Friday, March 1st. They issued a buy rating and a $2.30 target price on the stock.

OpGen stock opened at $0.56 on Tuesday. The company has a market cap of $4.86 million, a P/E ratio of -0.25 and a beta of 1.04. The company has a current ratio of 1.32, a quick ratio of 1.20 and a debt-to-equity ratio of 0.33. OpGen has a one year low of $0.53 and a one year high of $2.90.

OpGen (NASDAQ:OPGN) last announced its earnings results on Tuesday, February 26th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.09). OpGen had a negative net margin of 453.73% and a negative return on equity of 232.38%. Sell-side analysts expect that OpGen will post -0.93 EPS for the current year.

In other OpGen news, CEO Evan/ Fa Jones bought 417,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were bought at an average cost of $0.60 per share, with a total value of $250,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 7.10% of the company’s stock.

A hedge fund recently bought a new stake in OpGen stock. Bank of New York Mellon Corp purchased a new stake in OpGen Inc (NASDAQ:OPGN) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 20,688 shares of the medical research company’s stock, valued at approximately $27,000. Bank of New York Mellon Corp owned about 0.24% of OpGen at the end of the most recent quarter. Hedge funds and other institutional investors own 5.47% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Featured Story: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.